The Aesthetic Guide is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Surgical Innovation Associates Reports 1st US Patient Implanted in Pivotal IDE Study of DuraSorb Monofilament Mesh Use in Prosthetic Breast Reconstruction

Article-Surgical Innovation Associates Reports 1st US Patient Implanted in Pivotal IDE Study of DuraSorb Monofilament Mesh Use in Prosthetic Breast Reconstruction

Surgical Innovation Associates Reports 1st US Patient
Surgical Innovation Associates notes the study will evaluate the safety and effectiveness of DuraSorb for reinforcement in prosthetic breast reconstruction. The product is made from a biocompatible synthetic material to provide mechanical support and scaffolding during the early months of wound healing and scar formation, followed by gradual absorption, which is generally complete by one year.

Surgical Innovation Associates notes the study will evaluate the safety and effectiveness of DuraSorb for reinforcement in prosthetic breast reconstruction.

The product is made from a biocompatible synthetic material to provide mechanical support and scaffolding during the early months of wound healing and scar formation, followed by gradual absorption, which is generally complete by one year.1-4 While DuraSorb® received a CE mark for reconstructive and aesthetic breast surgery last year, no mesh product, DuraSorb or otherwise, currently has approval from the US FDA for breast reconstruction. Despite this, prosthetic breast reconstruction is most often performed with costly biologic mesh derived from the skin of human cadavers.5-7 DuraSorb® is designed to provide the same type of support during breast reconstruction, without requiring any cadaveric or animal-derived tissue.

“As plastic surgeons, we have been using processed human skin in breast surgery for over 15 years,” said Dr. Mihye Choi, an Associate Professor at New York University Hansjorg Wyss Department of Plastic Surgery, and the first principal investigator to enroll a patient in SIA’s pivotal study. “ADM has its benefits, but I am excited to use a non-biologic alternative that has been evaluated by the FDA for this specific purpose.”

The importance of this work is recognized by the National Cancer Institute, which is partially funding the clinical trial through the Small Business Innovation Research Program. In addition, the IDE study was approved by the Centers for Medicare and Medicaid, which will allow Medicare beneficiaries access to the trial.

 

Read more here.

 

Source:

Medical Device News Magazine

TAGS: Research
Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish